Reference : Glitazones et insuffisance cardiaque: resultats des etudes PROactive, ADOPT, DREAM et...
Scientific journals : Article
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Cardiovascular & respiratory systems
Human health sciences : Endocrinology, metabolism & nutrition
Glitazones et insuffisance cardiaque: resultats des etudes PROactive, ADOPT, DREAM et RECORD.
[en] Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials
De Flines, Jenny mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Scheen, André mailto [Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale >]
Revue Médicale Suisse
1876, 1878-83
Yes (verified by ORBi)
[en] Clinical Trials as Topic ; Diabetes Mellitus, Type 2/drug therapy ; Heart Failure/chemically induced ; Humans ; Hypoglycemic Agents/administration & dosage/adverse effects ; Thiazolidinediones/administration & dosage/adverse effects
[en] Thiazolidinediones (TZDs) are used as insulin sensitizers in the treatment of type 2 diabetes, but are associated with an increased risk of congestive heart failure (CHF). The odds ratio of ICC was 1.43 (pioglitazone vs placebo) in diabetic patients with high cardiovascular risk in the PROactive trial while it averaged 1.22 (rosiglitazone vs metformin) and 2.20 (rosiglitazone vs metformin) in the ADOPT study. In the interim analysis of the ongoing RECORD trial, the odds ratio averaged 2.15 (rosiglitazone vs metformin or sulfonylureas). In four real life registries, the relative risk of CHF with TZDs varied between 1.06 and 1.76 (between 1.10 and 1.44 combined with insulin) as compared to a treatment without TZDs. Such higher CHF risk should be appreciated according to the potential benefits of glitazones in the management of type 2 diabetes.

File(s) associated to this reference

Fulltext file(s):

Open access
Glitazones et insuffisance cardiaque_ocr.pdfAuthor postprint159.29 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.